Latest market news, earnings coverage, and analysis for HIMS (HIMS) from KAHROS.
Hims & Hers is cleaning up its GLP-1 strategy after February drama, partnering with Novo Nordisk to offer Ozempic and Wegovy on its platform.
Reports on March 9, 2026 suggest Novo Nordisk may sell weight-loss drugs on Hims & Hers’ platform—reshaping GLP-1 access and risk.
